A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
Overview
- Phase
- Phase 3
- Intervention
- TTVA
- Conditions
- Tetanus
- Sponsor
- CanSino Biologics Inc.
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Incidence of adverse reactions (AR).
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of Tetanus Vaccine, Adsorbed (TTVA) or control vaccine.
Detailed Description
Tetanus can be prevented with tetanus toxoid-containing vaccines (TT-containing vaccines, TTCVs), which are included globally in routine immunization programs for children, and in many countries at the time of prenatal care. China eliminated neonatal tetanus in 2012, but non-neonatal tetanus remains a serious public health problem. TT vaccine was first produced in 1924 and is used as a single antigen vaccine and combination vaccine component to prevent other vaccine-preventable diseases, including diphtheria, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b (Hib), and other vaccine-preventable diseases. Haemophilus influenzae type b (Hib).
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age and older, able to provide valid proof of identity for himself/herself.
- •Ability to understand the requirements and process of the study and to agree to participate in the clinical trial and to sign an informed consent form.
- •Ability to comply with the requirements of the clinical trial protocol and complete all follow-up studies.
Exclusion Criteria
- •Previously diagnosed tetanus infection.
- •Vaccination against tetanus or vaccines containing tetanus toxoid antigen components (e.g., DPT, DPT, RCV, etc.) within 5 years.
- •Axillary temperature \>37.0°C on the day of enrollment.
- •Women with a positive urine pregnancy test or during pregnancy or breastfeeding.
- •Women of childbearing age, male volunteers and male volunteers whose partner is a woman of childbearing age have a pregnancy plan or birth plan during the study period.
- •Persons suffering from thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy that may contraindicate intramuscular injection.
- •Suffering from serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, malignant tumors, serious infectious or allergic skin diseases, hypertension that cannot be controlled by medication (at the time of on-site measurement: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), and being in the period of acute disease or chronic disease activity within 7 days.
- •History of severe neurological disorders such as epilepsy, convulsions, encephalopathy, or history of psychiatric disorders.
- •Previous history of severe allergy to vaccination or medication (anaphylaxis, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction), etc.).
- •Allergy to certain components of the vaccine used in this clinical trial (mainly tetanus toxoid, aluminum hydroxide, sodium chloride, etc.) or allergy to the above components from previous vaccination.
Arms & Interventions
Tetanus Vaccine, Adsorbed (TTVA)
1 dose of (TTVA) (0.5ml)
Intervention: TTVA
Tetanus Vaccine, Adsorbed (TT)
1 dose of (TT) (0.5ml)
Intervention: TT
Outcomes
Primary Outcomes
Incidence of adverse reactions (AR).
Time Frame: 0-30 days after immunization
Positive serum conversions of anti-tetanus toxoid IgG antibodies.
Time Frame: 30 days after immunization
Secondary Outcomes
- Geometric mean multiplicity of increase (GMI) of anti-tetanus toxoid IgG antibodies in serum.(30 days after immunization)
- Incidence of adverse events (AE).(0-30 days after immunization)
- Positivity rate of anti-tetanus toxoid IgG antibodies in serum.(30 days after immunization)
- Incidence of serious adverse events (SAEs).(6 months post-immunization)
- Geometric mean concentration (GMC) of anti-tetanus toxoid IgG antibodies in serum.(30 days after immunization)
- Proportion of serum with anti-tetanus toxoid IgG antibody concentration ≥1.0 IU/ml(30 days after immunization)
- Incidence of AR.(30 minutes after immunization)
- Incidence of AE/AR.(0-7 days post-immunization)